Name:                        Roger Laham

Office Address:         BIDMC, Harvard medical School,
                                    East Campus, SL 423C
                                    330 Brookline Avenue, Boston, MA 02215

Home Address:          39 Kent street, #4
                                    Brookline, MA 02445

Telephone:                (617) 667-8800

E-Mail:                       rlaham@bidmc.harvard.edu            

FAX:                           (617)-632-7460

Place of Birth:           Beirut, Lebanon

Education:

1982                            Baccalaureate                          College des Frères Sacré-Coeur

1985                            Bachelor of Science                 American University of Beirut
                                    High Distinction

1989                            M.D.                                       American University of Beirut
                                    Distinction

Postdoctoral Training:

Internships and Residencies

1989-1990                   Intern, Department of Medicine
                                    Duke University Medical Center, Durham, NC

1990-1991                   Junior Resident, Department of Medicine
                                    Duke University Medical Center, Durham, NC

1991-1992                   Senior Resident, Department of Medicine
                                    Duke University Medical Center, Durham, NC

Clinical and Research Fellowships

1992-1994                   Clinical Fellow, Cardiovascular Division
                                    BIH, Harvard Medical School, Boston, MA

1994-1996                   Clinical Fellow, Interventional Cardiology Section
                                    BIH, Harvard Medical School, Boston, MA

1994-1996                   Fellow, Angiogenesis Research Center
BIH, Harvard Medical School, Boston, MA

Faculty Academic Appointments:

1992-1995                   Clinical Fellow in Medicine
                                    Harvard Medical School, Boston, MA

1995-1999                   Instructor in Medicine
                                    Harvard Medical School, Boston, MA

1999-2002                   Assistant Professor of Medicine
                                    Harvard Medical School, Boston, MA

2002-                           Associate Professor of Medicine
                                    Harvard Medical School, Boston, MA

2005-                           Faculty, Harvard Stem Cell Institute

2005-                           Faculty, CEC Committee,
                                    Harvard Clinical Research Institute, Boston, MA

2006                            Faculty, American Medical Foundation (peer review and quality
control)

Hospital Appointments:

1999                            Assistant Director, Interventional Cardiology
BIDMC, Boston, MA

1999-2001                   Director, Clinical Research
                                    Angiogenesis Research Center
BIDMC, Boston, MA

2001-2006                   IRB committee, Clinical Investigation Committee

2000-present               Director, Basic Angioplasty Research
Interventional Cardiology Section
BIDMC, Boston, MA

2002-2008                   Director, Cardiovascular Angiogenesis Research Center
BIDMC, Boston, MA

2007-present               Co-Director, Vascular Medicine and Endovascular Interventions

2009-present               Director, Structural Heart Center
                                    BIDMC, Harvard Medical School

Major Committee Assignments:

1988-1989                   Member, Continuing Education Committee
                                    American University

1995-1996                   Member, Committee on Bylaws
                                    Massachusetts Medical Society

1998-2005                   Member, Committee on Clinical Investigation
                                    BIDMC, Boston, MA

2000-2005                   Delegate, Massachusetts Medical Society

2000-2002                   Scientific Committee and Course Co-director, Vienna Annual Interdisciplinary scientific congress

2001-present               Scientific Committee, International Congress on Coronary Artery Disease

2000-present               Scientific Committee, International Coronary artery Disease Congress

2001-present               International Referee, Biomedical Research Council, Singapor

2002-present               National Referee, Department of Defense Research Program, Breast Cancer study section

2002-present               Society of Cardiac Angiography and Interventions Credentials Committee

2003-present               Reviewer for the NHLBI Program of Excellence in Gene Therapy (PEGT) National Cores

2003- present              Reviewer, GlaxoSmithKline fellowship Research and Development Fellowship Program

2004 - present             Reviewer FDA intramural program

2005-present               Reviewer for the NHLBI study section on cell based therapy

2006-present               Clinical Events Committee, Harvard Clinical Research
Institute

2011-                           Reviewer, NIH Small Business: Cardiovascular and Surgical
Devices Special Emphasis Panel

Professional Societies:

1993                            Member, Massachusetts Medical Society
1993                            Member, American Medical Association
1994                            Member, American College of Physician
1994                            Member, American College of Cardiology

1998                            Member, American Association for the Advancement of Science

1998                            Member, American Heart Association Council on Atherosclerosis,
Thrombosis, and Vascular Biology
1999                            Member, Society for Cardiac Magnetic Resonance Imaging
2000                            Delegate, Massachusetts Medical Society
2001                            Fellow, American Heart Association Council on Atherosclerosis,
Thrombosis, and Vascular Biology
2002                            Fellow of American Society for Cardiovascular Angiography and
Interventions (FSCAI)
2002                            Member, American Association for Advancement of Science
2003                            Fellow of the American College of Cardiology (FACC)
2005                            Fellow, Society for Vascular Medicine and Biology
2006                            Faculty, Harvard Stem Cell Institute
2006                            Fellow, American Heart Association Council on Cardiovascular
Radiology and Intervention

Grant Review Activities

2001-present               International Referee, Biomedical Research Council, Singapor

2002-present               National Referee, Department of Defense Research Program, Breast Cancer study section

2002-present               Society of Cardiac Angiography and Interventions Credentials Committee

2003-present               Reviewer for the NHLBI Program of Excellence in Gene Therapy (PEGT) National Cores

2003- present              Reviewer, GlaxoSmithKline fellowship Research and Development Fellowship Program

2004 - present             Reviewer FDA intramural program

2005-present               Reviewer for the NHLBI study section on cell based therapy

2011-                           Reviewer, NIH Small Business: Cardiovascular and Surgical
Devices Special Emphasis Panel

Editorial Activities:

1998-present               Associate Editor                                 Uptodate in Medicine

Interventional Cardiology                   Wellesley, MA

1999-present               Editorial Board                                    Cardiac and Vascular
Regeneration

1998-present               Editorial Board                                    CHF Disease Management

1998-present               Editorial Board                                    Complementary Therapies in
Chronic Care

2002-present               Editorial Board                                    Catheterization and
Cardiovascular Interventions

2003-present               Editorial Board                                    Cardiovascular Radiation                                                                                                        Medicine

1999-present               Ad-hoc reviewer                                  Circulation

1999-present               Ad-hoc reviewer                                  Journal of the American
College of Cariology

1999-present               Ad-hoc reviewer                                  Catheterization and
Cardiovascular Intervention

2000-present               Ad-hoc reviewer                                  Clinical and Experimental
Immunology

2000-present               Ad-hoc reviewer                                  American Journal of
Cardiology

2000-present               Ad-hoc reviewer                                  Cardiac and vascular
regeneration

2001-present               Ad-hoc reviewer                                  Journal of Pharmacology
and Experimental Therapy

2001-present               Ad-hoc reviewer                                  New England Journal
 of Medicine

2001-present               Ad-hoc reviewer                                  American Heart Journal

2001-present               Ad-hoc reviewer                                  American Journal of
Physiology

2002-present               Ad-hoc reviewer                                  The Lancet

2002-present               Ad-hoc reviewer                                  Am. J. of Cardiovascular
Drugs

2002-present               Ad-hoc reviewer                                  Trends in Molecular
Medicine

2002-present               Ad-hoc reviewer                                  Coronary Artery Disease

2003-present               Ad-hoc reviewer                                  Current gene therapy

2003-present               Ad-hoc reviewer                                  Gene Therapy (Nature)

2003-present               Ad-hoc reviewer                                  Diabetes

2004-present               Ad-hoc reviewer                                  Gene Therapy and Molecular
Biology

2004-present               Ad-hoc reviewer                                  Circulation Research

Honors and prizes:

1982-1989                   Dean's Honor List, American University of Beirut
1985                            Bachelor of Sciences with High Distinction, American University
of Beirut
1987-88                       Franklin Thomas Moore-Ethel Jessup Memorial Prize
                                    American University of Beirut
1987-88                       Munib Shahid Prize, American University of Beirut
1989                            Doctor of Medicine with Distinction, American University of Beirut, Ranked First
1989                            Penrose Award (for the best combination of the qualities                                                     of scholarship, character, leadership, and contribution to                                                            the University as a whole), American University of Beirut
1993-1996                   Physician’s Recognition Award, American Medical Association
1994-1995                   Hewlett-Packard Fellowship Award in Cardiovascular                                                         Research
1995                            American College of Cardiology/Bristol-Myers Squibb                                                         Affiliate Travel Award
1996-1999                   Physician’s Recognition Award, American Medical
                                    Association
1996                            The Altman Award Endowment Fund for Outstanding Talent as Clinician, Researcher, and Humanitarian Deliverer of Care, BIH, Harvard Medical School, Boston, MA
1996                            Merck Pharmaceuticals Travel Award
1999                            Plenary Lecture, Transcatheter Therapeutics Symposium
2001                            Plenary Lecture, Vienna Interdisciplinary Symposium
2001                            Plenary Lecture, Moscow Cardiology Summit
2001                            Plenary Lecture, American Heart Association meeting, Rockport, Maine
2001                            Plenary Lecture, Cardiac Magnetic Resonance Imaging Society Scientific Session
2001                            Keynote speaker, International Congress on Coronary artery disease
2002                            GCRC Award, presented at General Clinical Research Center, Center for Research Resources, NIH, Maryland
2002                            Allen Ephraim Diamond Lecturer (Keynote address), Toronto
2003                            Stafford Cohen development award
2005                            Dean’s International Council, University of Chicago Harris School of Policy
2005                            Kennedy School of Government, Dean’s Council
2006                            America's Top Doctors 6th edition (2006)
2007                            Center for Integration of Medicine and Innovative Technology
                                    Award
2007                            Massachusetts Technology Transfer Award for percutaneous valve development
2007                            America's Top Doctors (2007)
2008                            Boston’s Magazine Top Doctor in Interventional Cardiology
2008                            America's Top Doctors (2008)
2008                            Patients’ Choice Award 2008
2009                            Patients’ Choice Award 2009
2009                            America’s Leading Experts in Myocardial Ischemia (2009)
2010                            America's Top Doctors
2010                            Boston Magazine Top Doctor in interventional cardiology

Patents:

2004-                           Methods and compositions for treating
conditions involving abnormal angiogenesis
using RTEF-1

2005-                           METHODS TO EXCLUDE LEFT ATRIAL APPENDAGE IN
TREATMENT OF ATRIAL FIBRILLATION-Issued

2006-                           DEVICES AND METHODS FOR TISSUE TRANSPLANT AND
REGENERATION

2006-                           DEVICES AND METHODS FOR CARDIAC
RESTRAINT AND TREATMENT OF HEART DILATION AND FAILURE

2007-                           DEVICES AND METHODS FOR PERCUTANEOUS VALVE REPLACEMENT

Report of Funded and Unfunded Projects

Research Activity:

Bench Research:

Outcome Research:

Clinical trials: (Most of the current clinical trials are also listed in current funding)

Report of Local Teaching and Training:

Advisory  and Supervisory Responsibilities in Clinical or Laboratory Setting:

Clinical

• Two days a week attending in the Catheterization laboratory with diagnostic, interventional, and peripheral vascular disease cases.   Supervision of 3-4 cardiology fellows. 20 hours/week
• Weekly Clinic for general cardiology and evaluation of patients with end stage cardiac diseaseperipheral Vascular Disease, and Structural Heart Disease.  4 hrs/weeks.
• One weekend per 2 months and one weeknight a week covering Cardiac catheterization laboratory for urgent and emergent cases.  Supervision of 2 fellows.  5 hours/week
• Four weeks of coronary care unit coverage and 4 weeks of CMI cardiology coverage.  Supervision of cardiology fellows, 4 residents and interns, and 1-2 medical students. 60 hrs/week.
• Weekly cardiac catheterization conference, clinical cardiology conference educating divisional faculty and fellows. 3 hour/week.
• Monthly National/International meeting presenting clinical data and proctoring other physician on the use of new devices.  10 hours/month

Laboratory

• IACUC approved animal facility with 2 active animal protocols (small and large animals).  Supervision of two postdoctoral fellows and one technician.  6 hours/week.
• Weekly laboratory meeting.  1 hr/week
• Monthly National/International meetings presenting novel research findings.  4 hours/month

5. Trainees (impact on career):

 
Local (BIDMC/HMS):

2. Regional:

3. National and International contributions:

Teaching Narrative:  Teaching responsibility has involved mainly the supervision and instruction of nurse practitioners, medical students, housestaff, and fellows in the division of cardiology and Department of Medicine at BIDMC, and at Harvard Medical School in clinical cardiology, interventional cardiology, Internal Medicine and translational research.  Teaching has involved 7 nurse practitioners, 20 medical interns and residents, and 8 medical students that are rotating through the clinical services attended, including the coronary care unit and the cardiology units.  This also included lectures given to medical interns, residents, cardiology fellows and medical students about interventional cardiology and angiogenesis.  The number of hours spent yearly preparing and delivering these teaching responsibilities approximates 7 hours weekly.
Other teaching contributions include the instruction of physician in the U.S., Canada, Europe, Asia, and the Middle East in performing advanced interventional procedures including electromechanical left ventricular mapping, various Atherectomy techniques, crossing total occlusions, intramyocardial injections, distal protection, high risk interventions, peripheral vascular interventions, structural heart disease interventions.  I serve as a mentor to a number of trainees.  I also serve on the scientific committee of several teaching courses for medical professionals nationally and internationally.  In addition, I travel, proctor, and collaborate with several leading researchers/Clinicians in Europe (England, Norway, Sweden, Germany, France, Netherland, Poland, Russia,..), Middle East (Saudi Arabia, United Arab Emirates, Jordan, Syria,…), Asia (China, Japan, Korea, Hong Kong, Singapore,..), North Africa, and South America

Report of Clinical Activities and Innovations

Current Licensure and Certification

1989, 1992,1994         Certified, Advanced Cardiac Life Support
1996, 2001, 2004,       American Heart Association
2007, 2009     

1992                            Diplomat, American Board of Internal Medicine
                                    Internal Medicine

1992-present               State of Massachusetts Medical License

1995                            Diplomat, American Board of Internal Medicine
                                    Cardiovascular specialty

1999                            Diplomat, American Board of Internal Medicine
                                    Interventional Cardiology

2004                            Recertified, American Board of Internal Medicine
                                    Internal Medicine

2005                            Recertified, American Board of Internal Medicine
                                    Cardiovascular specialty

2010                            Recertified, American Board of Internal Medicine
                                    Interventional Cardiovascular

2010                            Certified, American Board of Vascular Medicine, Endovascular
Diplomate

2011                            Recertified, American Board of Internal Medicine
                                    Interventional Cardiology

Practice Activities

• Interventional cardiology with catheter based cardiovascular revascularization and Critical care cardiology at BIDMC. 
• Patient load in the cardiac catheterization laboratory is in the high volume operator category with 225 complex interventional coronary cases yearly with 100 Peripheral vascular Intervention yearly including carotid Interventions and EVAR, and 100 structural heart disease cases including percutaneous valves, Atrial Septal Defect closure, Ventricular Septal Defect closure, PFO closure, ethanol septal ablation,….  Case complexity is high and many cases are referred by practicing interventional cardiologists for higher skill level intervention and high risk interventions Nationally and Internationally.
• Defining the long-term outcome of stenting, the main device used in interventional procedures and developing new devices for coronary, structural heart disease, and peripheral interventions. 
• Refining electromechanical mapping, laser myocardial revascularization, and intramyocardial injections techniques including cell based therapy and gene transfer investigation.
• Perform ethanol ablation as a treatment for hypertrophic cardiomyopathy
• Perform high risk interventions on no-option patients including unprotected left main intervention, occluded vein grafts, balloon vavuloplasty
• Treatment of Chronic total occlusion
• Treatment of PFO, ASD, VSD, PDA using occluder devices, percutaneous valves
• Proctoring of interventional cardiologists in intramyocardial injection, rotational atherectomy, distal protection, high risk intervention, Peripheral vascular Disease, Structural Heart Disease. 
• Recognition of a Leadership position in the field of Interventional cardiology, Peripheral Vascular Disease treatment, structural heart disease treatment, clinical angiogenesis, stem cell therapy, drug delivery, and high risk revascularization, with invited lectures in most interventional cardiology meetings both Nationally and Internationally.
• Recognition of a Leadership position in the field of clinical Myogenesis and Myocardial regeneration, with invited lectures in most interventional cardiology meetings both Nationally and Internationally.

Clinical Innovations

Developed and introduced several new procedures and imaging modalities at BIDMC including:

1. Ethanol septal ablation for hypertrophic cardiomyopathy
2. Congenital defect closure (ASD, VSD, PFO)
3. Left ventricular support devices including Tandem heart and Impella
4. Complex supported interventions
5. Foreign body retrieval
6. Ultrasound guidance for vascular access
7. 4Fr diagnostic catheterization
8. Intracardiac US for Interventional Use
9. Novel peripheral procedures including novel endovascular repair of abdominal aneurysms strategies
10. Using PET/CT for vulnerable plaque imaging
11. Cardiac CT
12. Percutaneous valves

Report of Technological and Other Scientific Innovations

Since joining the fellowship program and then the faculty rank BIDMC/Harvard Medical School, my research activities centered on translational research in vascular biology, angiogenesis, myogenesis, imaging and new device development.  These efforts have taken the form of basic research projects focused on restenosis and the endothelial responses to angiogenic growth factors, animal research projects focused on physiologic assessment of coronary angiogenesis in porcine models of myocardial ischemia and murine models of acute myocardial infarction, drug delivery research, cell and stem-cell based therapy, myotissue transplantation, clinical trials testing efficacy of angiogenic growth factors and new devices in patients with advanced coronary disease and congestive heart failure, and imaging of coronary disease (Multidetector CT), IVUS, and PET/CT for vulnerable plaque imaging, structural heart disease and percutaneous valves.  My research was funded by a Hewlett-Packard fellowship award (1995), a career development award program (CAP) from the General Clinical Research Center, NCRR (1997-2000 and then 2000-2002), a project I lead in a SCOR program (2000-2005), a CIMIT proof of principle award (2006-2011), and a Massachusetts Technology Transfer office Award for percutaneous valve development (2008-2011), as well as industry funding.  Eighteen of my former trainees now hold faculty rank in academic institutions in the US and abroad and every one of my trainees have had research presentations at major national meetings (AHA, ACC, TCT, etc.).  My current basic research efforts are concentrated on understanding the mechanism of action of novel angiogenic cytokines in vitro (matrigel models and migration assays) and in vivo using small animal models of myocardial infarction (mouse MI model), microorgan, myotissue transplantations and cord blood transplantation. We are currently investigating the role of exercise in the development of collaterals and overexpression of FGF and VEGF and their receptors in mice models of myocardial infarction.  In addition, SDF-1, Cord blood derived stem cell, APC, microorgans, myotissue, cardiac stem cells are ongoing.   Large animal studies have focused on local delivery of angiogenic agents to the heart, but more recently, we are investigating cell based therapy and myotissue transplantation in large animal models for myocardial regeneration and myocardial ischemia.  This work will be the basis of an investigator/industry sponsored IND/IDE for the investigation of cell based therapy for heart failure. Another involves basic, preclinical, and clinical experimentation of the effect of B-Natriuretic peptide on endothelial function and proliferation, coronary microvascular resistance, coronary blood flow, and epicardial tone.  I am also investigating the role of multidetector CT angiography in coronary imaging and PET/CT in vulnerable plaque imaging.
I am developing new devices and hold patents for percutaneous aortic valve replacement, myocardial regeneration, percutaneous left atrial appendage exclusion, and percutaneous myocardial restraining device.  I am the principal investigator on several clinical studies including new device trials and angiogenesis trials.  My research efforts have been recognized by my peers as publications in several peer-reviewed journal as well as presentations at most National and International meetings in Cardiology.  I have delivered several keynote and plenary presentations and I am asked to review manuscripts and grant proposals from several prestigious journals and funding agencies.                

Program Building: 

1. Helped establish Angiogenesis Research Center, a multidisciplinary program for growing new blood vessels to Heart and Vasculature with a robust translational program.  Several bench to bedside projects were carried out and numerous advancements in the filed were accomplished. 
2. Helped establish oversight on clinical Investigation and Human protection during tenure on institutional Review Board setting benchmarks for review process. 
3. Helped establish benchmarks for Cardiology and Vascular Practice, with programmatic, process, and peer review to identify suboptimal delivery of care and inappropriate practice patterns.
4. Helped implement physician and practice reporting both to Department of public Health and National databases in an effort to optimize delivery of care.  This set the stage for public reporting of outcomes, comparisons between observed and predicted mortality and morbidity, and outcome based reimbursement.  Examples include Door to balloon time for myocardial infarction, Door to Needle time for stroke, prevention of hospital acquired infections, infection clusters, Occupational safety,…
5. Helped establish gene therapy (preclinical and clinical studies) stem cell therapy for heart and vascular disease
6. Established Structural Heart Center, a collaborative effort between cardiac surgery, cardiology, vascular surgery, anesthesia, and radiology that enabled the surgical and non surgical treatment of congenital and acquired heart defects including percutaneous (catheter based valves, atrial and ventricular septal occluders, ..) and minimally invasive (robotic surgery, key hole incisions, Natural orifice access,…)
7. Studied and helped implement economic analysis of various therapeutic strategies with an emphasis on resource utilization, cost-effective analysis, cost-containment (early discharge, outpatient surgeries, outcome based reimbursement, certificate of need,…)

 
Report of Scholarship

Peer reviewed publications in print or other media
1.  Metoprolol in Dilated Cardiomyopathy Trial Study Group.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.  Lancet 1993;342:1441-1446.

2.  Laham RJ, Ho KKL, Douglas PS, Faherty CE, Lock JE, Baim DS, Kuntz RE.  Right ventricular infarction complicated by acute right-to-left shunting.  American Journal of Cardiology 1994;74:824-6.

3.  Laham RJ, Carrozza JP, Baim DS.  Treatment of unprotected left main stenoses with Palmaz-Schatz stenting.  Catheterization and Cardiovascular Diagnosis 1996;37:77-80.

4.  Laham RJ, Cohen DJ, Kuntz RE, Baim DS, Simons M.  Pericardial Effusion in Patients with cancer: natural history and management strategies.  British Heart Journal (Heart), 1996;75:67-71.

5.  Laham RJ, Carrozza JP, Berger CJ, Cohen DJ, Baim DS.  Long-term (4-6 year) outcome of Palmaz-Schatz coronary stenting.  Journal of the American College Cardiology1996;28:820-6.

6.  Sukin CA, Baim DS, Caputo RP, Ho KKL, Laham RJ, Flatley MG, Carrozza JP, Cohen DJ.  The impact of optimal stenting techniques on cardiac catheterization laboratory resource utilization and costs.  American Journal of Cardiology 1997;79:275-80. 

7.  Laham RJ, Ho KK, Baim DS, Kuntz RE, Cohen DJ, Carrozza JP.  Multivessel Palmaz-Schatz stenting: early results and one-year outcome.  Journal of the American College Cardiology1997:30: 180-5.

8.  Lopez JJ, Laham RJ, Carrozza JP, Tofukuji, Sellke FW, Bunting S, Simons M.  Hemodynamic Effects of Intracoronary VEGF Delivery- Evidence of Tachyphylaxis and NO Dependence of Response.  American Journal of Physiology 1997;273:H1317-23.

9. Pearlman JD, Laham RJ, Simons M, Gladstone S, Raptopoulos VD.  3D elastic spiral CT definition of myocardial collateralization extent.  Academic Radiology 1997;4:680-6.

10.  Li J, Brown LF, Laham RJ, Simons M.  Macrophage-dependent regulation of syndecan gene expression.  Circulation Research 1997;81:785-96.

11. Sellke FW, Tofukuji M, Laham RJ, Li J, Hariawala MD, Bunting S, Simons M.  Comparison of surgical and catheter-based techniques of VEGF delivery on myocardial perfusion and endothelium-dependent relaxation.  Microvascular Research 1997;55:175-77.
12.  Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M.  Therapeutic angiogenesis with basic fibroblast growth factor:  technique and early results.  Annals Thoracic Surgery 1998;65:1540-4.

13.  Lopez JJ, Laham RJ, Stamler A,  Pearlman JD, Bunting S, Kaplan A, Carrozza JP, Sellke FW, Simons M. Therapeutic Angiogenesis in Chronic Myocardial Ischemia: Intracoronary vs. Extracoronary Delivery Strategies.  Cardiovascular Research 1998;40:272-81.

14. Laham RJ, Simons M, Tofukuji M, Hung D, Sellke FW.  Modulation of Myocardial Perfusion and Vascular Reactivity by Pericardial Basic Fibroblast Growth Factor: Insight into ischemia-induced reduction in endothelium-dependent vasodilatation.  Journal of Thoracic and Cardiovascular Surgery 1998;116:1022-8.

15.  Daeurman HL, Higgins PJ, Sparano AM, Gibson M, Garber GR, Carrozza JP, Kuntz RE, Laham RJ, Shubrooks SJ, Baim DS, Cohen DJ.  Mechanical debulking versus balloon angioplasty for the treatment of true bifurcation lesions.  Journal of the American College Cardiology 1998;7:1845-52.

16. Laham RJ, Hung D, Simons M. Subxyphoid Access of the Normal Pericardium: A Novel Drug Delivery Technique.  Catheterization and Cardiovascular Diagnosis 1999;47:109-11.

17.  Laham RJ, Hung D, Simons M.  Therapeutic myocardial angiogenesis using percutaneous intrapericardial drug delivery.  Clinical Cardiology 1999;22:6-9.

18. Gibson CM, Ryan K, Sparano A, Moynihan JL, Rizzo M, Kelley M, Marble SJ, Laham RJ, Simons M, McClusky TR, Dodge JT, Jr.  Angiographic methods to assess human coronary angiogenesis. American Heart Journal 1999;137(1):169-79.

19.  Zimetbaum PJ, Schreckengost VE, Cohen DJ, Lemery R, Love D, Epstein LM, Laham RJ, Josephson ME. Evaluation of outpatient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation. American Journal of Cardiology 1999;83(3):450-2.

20. Laham RJ, Rezaee M, Post M, Sellke FW, Braeckman RA, Hung D, Simons M. Myocardial and tissue distribution of intracoronary and intravenous bFGF.  Drug Metabolism and Distribution 1999;27:821-6.

21.  Baim DS, Carrozza JP, Jr., Kuntz RE, Laham RJ. Managing the embolization problem during saphenous vein graft intervention. Catheterization and Cardiovascular Interventions 1999;47:155-6.

22. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown D, Gold J, Simons M.  Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery: Results of a Phase I Randomized, Double-Blind, Placebo-Controlled Trial.  Circulation 1999;100:1865-71.

24.  Laham RJ, Rezaee M, Post M, Novicki D, Sellke FW, Pearlman JD, Simons M, Hung D.  Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia.  Journal of Pharmacology and Experimental Therapeutics 2000;292:795-802.

25.  Pearlman JD, Laham RJ, Simons M. Coronary angiogenesis: detection in vivo with MR imaging sensitive to collateral neocirculation--preliminary study in pigs. Radiology. 2000;214:801-7.

26.  Laham RJ, Simons M.  Laser Myocardial Revascularization, fact or fiction.  Cardiac and vascular Regeneration 2000;1:70-2.

27.  Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, Pettigrew RI, Whitehouse MJ, Yoshizawa C, Simons M.  Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease:  Results of a Phase I open label dose escalation study.  Journal of the American College Cardiology  2000;36:2132-9.

28.  Simons M, Bonow R, Chronos NA, Cohen DJ, Giordano F, Hammond K, Laham RJ, Li W, Pike M, Sellke FW, Stegmann T, Udelson JE, Rosengartt T.  Clinical Trials in Coronary Angiogenesis- Issues, Problems, Consensus Expert panel summary.  Circulation 2000:102:e73-86.

29.  Kornowski R, Baim DS, Moses JW, Hong MK, Laham RJ, Fuchs S, Hendel RC, Wallace D, Cohen DJ, Bonow RO, Kuntz RE, Leon MB. Short- and intermediate-term clinical outcomes from direct myocardial laser revascularization guided by biosense left ventricular electromechanical mapping. Circulation 2000;102:1120-5.

30.  Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605-10.

31.  Sato K, Laham RJ, Pearlman JD, Novicki D, Sellke FW, Simons M, Post MJ.  Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia.  Annals Thoracic Surgery 2000;70:2113-8.   

32.  Post MJ, Sato K, Kornowski R, Epstein SE, Leon MB, Baim DS, Simons M, Laham RJ.  Adenovirus-mediated gene therapy through intramyocardial injections:  Percutaneous intramyocardial versus surgical epicardial delivery.  Cardiac and vascular Regeneration  2000;1:106-13.
 
33.  Laham RJ, Post M, Sellke FW, Simons M. Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery. Current Interventional Cardiology Reports 2000;2:213-217.

34.  Sato K, Wu T, Laham RJ, Johnson RB, Douglas P, Li J, Sellke FW, Bunting S, Simons M, Post M.  Efficacy of Intracoronary or Intravenous VEGF165 in a Pig Model of Chronic Myocardial Ischemia.  Journal of the American College Cardiology 2001;37:616-23.  

35.  Fuchs S, Hendel RC, Baim DS, Moses JW, Pierre A, Laham RJ, Hong MK, Kuntz RE, Pietrusewicz M, Bonow RO, Mintz GS, Leon MB, Kornowski R. Comparison of endocardial electromechanical mapping with radionuclide perfusion imaging to assess myocardial viability and severity of myocardial ischemia in angina pectoris. Am J Cardiol 2001;87:874-880.

36.  Xu X, Li J, Simons M, Laham RJ, Sellke FW. Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia. J Thorac Cardiovasc Surg. 2001;121:735-42.

37.  Laham RJ, Baim DS.  Combined Percutaneous Biosense-guided Laser Myocardial Revascularization and Coronary Intervention. Catheterization and Cardiovascular Interventions 2001;53:235-40.

38.  Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA. Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease. J Clin Pharmacol. 2001;41:378-85.

39.  Bao J, Naimark W, Palasis M, Laham R, Simons M, Post MJ. Intramyocardial delivery of FGF2 in combination with radio frequency transmyocardial revascularization. Catheter Cardiovasc Interv 2001;53:429-34.

40.  Laham RJ, Simons M, Sellke F. Gene transfer for angiogenesis in coronary artery disease. Annu Rev Med. 2001;52:485-502.

41.  Laham RJ, Mannam A, Post MJ, Sellke F. Gene transfer to induce angiogenesis in myocardial and limb ischaemia. Expert Opin Biol Ther 2001;1:985-94.

42.  Pearlman JD, Laham RJ, Post M, Leiner T, Simons M. Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis. Curr Pharm Des. 2002;8:1467-96.

43.  Khan TA, Sellke FW, Laham RJ. Therapeutic Angiogenesis for Coronary Artery Disease.  EOBT 2002;4:65-74.

44.  Laham RJ, Simons M, Pearlman JD, Ho KKL, Baim DS.  Magnetic Resonance Imaging Demonstrates Improved Regional Systolic Wall Motion and Thickening and Myocardial Perfusion of Myocardial Territories Treated by Laser Myocardial Revascularization.  Journal of the American College of Cardiology, 2002:1-8.

45.  Simons M, Annex B, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino E, Pike P, Whitehouse MJ, Moon T, Chronos NA.  Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2.  Circulation 2002;105:788-93.

46.  Mannam AP, Ho KKL, Cultip DE, Carrozza JP, Cohen DJ, Lorell BH, Laham RJ.  Safety of Subxyphoid Pericardial Access Using a Blunt-tip Needle.  American Journal of Cardiology 2002;89:891-3.

47.  Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M. The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis. Clin Cardiol. 2002;25:271-8.

48.  Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, Sellke FW. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002;124:28-34.

49.  Rinfret S, Cutlip D, Katsiyiannis PT, Ho KKL, Cohen DJ, Carrozza JP, Laham RJ.  Rheolytic Thrombectomy and Platelet Glycoprotein IIb/IIIa Blockade for Stent Thrombosis.  Catheterization and Cardiovascular Interventions 2002;57:24-30.

50.  Rinfret S, Katsiyiannis P, Ho KKL, Cohen DJ, Baim DS, Carrozza JP, Laham RJ.  Rheolytic Coronary Thrombectomy with the AngioJet Catheter: A Large Single-Center Experience from a Non-Selected Population.  American Journal of Cardiology 2002;90:470-6.

51.  Laham RJ, Oettgen P. Bone marrow transplantation for the heart: fact or fiction? Lancet. 2003;361:11-2.

52.  Khan TA, Sellke FW, Laham RJ. Therapeutic angiogenesis: protein-based therapy for coronary artery disease. Expert Opin Pharmacother. 2003;4:219-26.

53.  Khan TA, Sellke FW, Laham RJ.  Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia.  Nature Gene Therapy 2003;10:285-91

54.  Laham RJ, Rezaee M, Post M, Xu X, Sellke FW.  Intrapericardial Administration of Basic Fibroblast Growth Factor: Myocardial and Tissue Distribution and Comparison with Intracoronary and Intravenous Administration. Catheterization and Cardiovascular Interventions 2003;58:375-81.

55.  Laham RJ, Li J, Tofukuji M, Post M, Simons M, Sellke FW. Spatial heterogeneity in VEGF-induced vasodilation: VEGF dilates microvessels but not epicardial and systemic arteries and veins. Ann Vasc Surg. 2003;17:245-52.
56.  Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Laham RJ, Sellke FW. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Circulation. 2003;108 Suppl 1:II335-40.

57.  Abner AL, Holupka EJ, Laham R, Bues M. Treatment of in-stent restenosis at a bifurcation: determination of optimal source positioning using electron beam computed tomography (EBCT) and monte carlo dose calculation. Int J Radiat Oncol Biol Phys. 2003;57:S249-50.

58.  Wu G, Mannam AP, Wu J, Kirbis S, Shie JL, Chen C, Laham RJ, Sellke FW, Li J. Hypoxia Induces Myocyte-dependent COX-2 Regulation in Endothelial Cells -Role of VEGF. Am J Physiol Heart Circ Physiol. 2003;285:H2420-9
           
59.  Khan TA, Sellke FW, Laham RJ. Therapeutic angiogenesis: protein-based therapy for coronary artery disease. Expert Opin Pharmacother. 2003;4:219-26.

60.  Wu J, Parungo C, Wu G, Kang PM, Laham RJ, Sellke FW, Simons M, Li J. PR39 Inhibits Apoptosis in Hypoxic Endothelial Cells. Role of Inhibitor Apoptosis Protein-2. Circulation. 2004;109:1660-7.

61.  Shie JL, Wu G, Wu J, Liu FF, Laham RJ, Oettgen P, Li J. RTEF-1, a novel transcriptional stimulator of VEGF in hypoxic endothelial cells. J Biol Chem. 2004.

62.  Rosinberg A, Khan TA, Sellke FW, Laham RJ. Therapeutic angiogenesis for myocardial ischemia. Expert Rev Cardiovasc Ther. 2004;2:271-83.

63.  Voisine P, Bianchi C, Ruel M, Malik T, Rosinberg A, Feng J, Khan TA, Xu SH, Sandmeyer J, Laham RJ, Sellke FW. Inhibition of the cardiac angiogenic response to exogenous vascular endothelial growth factor. Surgery. 2004;136:407-15.

64.  Laham RJ. Yet another "weapon" to conquer the last remaining challenge in PCI. Catheter Cardiovasc Interv. 2004;63:164-5.

65.  Rana J, Mannam A, Donnel-Fink L, Gervino EV, Sellke F, Laham RJ. Longevity of the Placebo Effect in the Therapeutic Angiogenesis and Laser Myocardial Revascularization Trials in Patients with Coronary Heart Disease. Am J Cardiol 2005;95:1456-1459.

66.  Laham RJ, Post M, Rezaee M, Donnel-Fink L, Wykrzykowska J, Lee SU, Baim DS and Sellke F.  Transendocardial and trans-epicardial intramyocardial FGF-2 administration: Myocardial and Tissue Distribution. Drug Metab Dispos 2005; In Press

67.  Sellke F, Laham RJ, Voisine P, Ruel M. Therapeutic angiogenesis for the treatment of coronary artery disease: can we improve the results. J Jpn Coll Angiol. 2005;45:221-232.

68.  Laham RJ. Drug eluting stents for everyone and everything? Catheter Cardiovasc Interv. Dec 2005;66(4):512-513.

69.  Leon MB, Kornowski R, Downey WE, Weisz G, Baim DS, Bonow RO, Hendel RC, Cohen DJ, Gervino E, Laham R, Lembo NJ, Moses JW, Kuntz RE. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol. Nov 15 2005;46(10):1812-1819.

70.  Wu G, Luo J, Rana JS, Laham R, Sellke FW, Li J. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res. Feb 1 2006;69(2):512-519.

71.  Wu G, Du Z, Hu C, Zheng Z, Zhan C, Ma H, Fang D, Ahmed KT, Laham RJ, Hui JC, Lawson WE. Angiogenic effects of long-term enhanced external counterpulsation in a dog model of myocardial infarction. Am J Physiol Heart Circ Physiol. Jan 2006;290(1):H248-254.

72.  Boodhwani M, Ramlawi B, Laham RJ, Sellke FW. Targeting vascular endothelial growth factor in angina therapy. Expert Opin Ther Targets. Feb 2006;10(1):5-14

73.  Lee SU, Wykrzykowska JJ, Laham RJ. Angiogenesis: bench to bedside, have we learned anything? Toxicologic pathology. 2006;34(1):3-10.

74.  Wykrzykowska JJ, Kwaku K, Wylie J, Manning WJ, Josephson ME, Zimetbaum P, Laham RJ. Delayed Occurrence of Unheralded Phase IV Complete Heart Block After Ethanol Septal Ablation for Symmetric Hypertrophic Obstructive Cardiomyopathy. Pacing Clin Electrophysiol. Jun 2006;29(6):674-678. 

75. Boodhwani M, Nakai Y, Voisine P, Feng J, Li J, Mieno S, Ramlawi B, Bianchi C, Laham R, Sellke FW. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation. 2006;114 (1):I402-408.

76.  Mieno S, Boodhwani M, Ramlawi B, Li J, Feng J, Bianchi C, Laham RJ, Li J, Sellke FW. Human coronary microvascular effects of cardioplegia-induced stromal-derived factor-1alpha. Ann Thorac Surg. 2006;82(2):657-663.

77.  Sperling RT, Ho K, James D, Laham R, Gibson M, Carrozza J. Treatment of stent-jailed side branch stenoses with rotational atherectomy. J Invasive Cardiol 2006;18(8):354-358.

78.  Wykrzykowska JJ, Carrozza J, Laham RJ. Aortocoronary dissection with acute left main artery occlusion: successful treatment with emergent stenting. J Invasive Cardiol 2006;18(8):E217-220.

79.  Boodhwani M, Sodha NR, Laham RJ, Sellke FW. The Future of Therapeutic Myocardial Angiogenesis. Shock Oct 2006;26(4):332-341.

80.  Sellke FW, Laham RJ, Suuronen EJ, Ruel M. Angiogenesis for the treatment of inoperable coronary disease: the future. Semin Cardiothorac Vasc Anesth 2006;10(2):184-188.

81.  Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP, Jr., Antman EM, Cannon CP, Gibson CM. Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction. Implications When Selecting a Reperfusion Strategy. Circulation  2006;114:2019-25.

82.  Voisine, P, Rosenberg A, Wykrzykowska J, Shamis Y, Wu GF, Appelbaum E, Li J, Sellke FW, Pinto D, Gibson CM, Mitrani E, Laham RJ.  Skin-Derived Micro-organ Auto-transplantation as a Novel Approach for Therapeutic Angiogenesis.  Am J Physiol Heart Circ Physiol. Jan 2008;294(1):H213-219.

83.  Wykrzykowska J, Williams M, Laham RJ.  Stabilization of renal function, improvement in blood pressure control and pulmonary edema symptoms after opening of a totally occluded renal artery.   J Invasive Cardiol. 2008 Jan;20(1):E26-9.

84.  Laham RJ.  Anecdotal vs. evidence-based, off label use of drug eluting stents for infrapopliteal disease: Abusus non tollit usum (Misuse does not nullify proper use).  Catheter Cardiovasc Interv. 2008 Jan 1;71(1):112-113.

85.  Wykrzykowska J, Piazza G, Laham RJ.  Intracavitary Pressure Wire and Intracardiac Ultrasound for the Evaluation of Combined Symmetric Hypertrophic Cardiomyopathy and Aortic Stenosis in a Patient with Dyspnea and Syncope: Treatment with Ethanol Septal Ablation.  J Invasive Cardiol. May 2008;20(5):E171-173.

86.  Wu GF, Wykrzykowska JJ, Rana JS, Pinto DS, Gibson CM, Li J, Sellke FW, and Laham RJ. Effects of B-type natriuretic peptide (nesiritide) on coronary epicardial arteries, systemic vasculature and microvessels. J Invasive Cardiol 2008;20: 76-80.

87.  Sodha NR, Clements RT, Boodhwani M, Xu SH, Laham RJ, Bianchi C, Sellke FW. Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am J Physiol Heart Circ Physiol. 2009;296(2):H428-434.

88.  Wu GF, Rana J, Wykrzykowska JJ, Ke Q, Kang P, Li J, Laham RJ. 
Exercise-Induced Expression of VEGF and Salvation of Myocardium in the Early Stage of Myocardial Infarction.   Am J Physiol Heart Circ Physiol. 2009; 296(2):H389-395.

89.  Wykrzykowska JJ, Lehman S, Williams G, Parker JA, Palmer M, Varkey SC, Kolodny G, Laham RJ.  Imaging of Inflammatory/Vulnerable plaque in coronary arteries with 18FDG PET/CT in patients with suppression of myocardial uptake using a low carbohydrate, high fat preparation.  J Nuclear Medicine 2009; 50:563-568.

90. Laham RJ. The Treatment of Peripheral Vascular Disease: Scio me nihil scire.  J Invasive Cardiol 2009: 21( 6): 282.

91.  Robich MP, Chu LM, Chaudray M, Nezafat R, Han Y, Clements RT, Laham RJ, Manning WJ, Coady MA, Sellke FW. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery. 2010; 148: 453-462.

92 . Robich MP, Matyal R, Chu LM, Feng J, Xu SH, Laham RJ, Hess PE, Bianchi C, Sellke FW. Effects of Neuropeptide Y on collateral development in a swine model of chronic myocardial ischemia. J Mol Cell Cardiol. 2010;49:1022-1030

93.  Robich MP, Chu LM, Feng J, Burgess TA, Laham RJ, Bianchi C, Sellke FW. Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium. J Thorac Cardiovasc Surg. 2010;140:1143-1152

94.  Robich MP, Osipov RM, Chu LM, Feng J, Burgess TA, Oyamada S, Clements RT, Laham RJ, Sellke FW. Temporal and Spatial Changes in Collateral Formation and Function During Chronic Myocardial Ischemia. J Am Coll Surg. 2010;211:470-480

95.  Ma X, Oyamada S, Gao F, Wu T, Robich MP, Wu H, Wang X, Buchholz B, McCarthy S, Gu Z, Bianchi CF, Sellke FW, Laham R. Paclitaxel/sirolimus combination coated drug-eluting stent: In vitro and in vivo drug release studies. J Pharm Biomed Anal. 2011;54:807-811

96.  Robich MP, Osipov RM, Nezafat R, Feng J, Clements RT, Bianchi C, Boodhwani M, Coady MA, Laham RJ, Sellke FW. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation. 2010;122:S142-149

97.  Wykrzykowska JJ, Rosinberg A, Lee SU, Voisine P, Wu G, Appelbaum E, Boodhwani M, Sellke FW, Laham RJ. Autologous cardiomyotissue implantation promotes myocardial regeneration, decreases infarct size, and improves left ventricular function. Circulation. 2011;123:62-69

98. Oyamada S, Ma X, Wu T, Robich MP, Wu H, Wang X, Buchholz B, McCarthy S, Bianchi CF, Sellke FW, Laham R. Trans-iliac rat aorta stenting: A novel high throughput preclinical stent model for restenosis and thrombosis. J Surg Res. 2010

99.  Ma X, Oyamada S, Wu T, Robich MP, Wu H, Wang X, Buchholz B, McCarthy S, Bianchi CF, Sellke FW, Laham R. In vitro and in vivo degradation of poly(d, l-lactide-co-glycolide)/amorphous calcium phosphate copolymer coated on metal stents. J Biomed Mater Res A. 2011

100.  Dejam A, Hokinson M, Laham R. Repeated successful balloon valvuloplasty of a bioprosthetic aortic valve in a nonagenerian. Catheter Cardiovasc Interv. 2011;77:589-592

101.  Chu LM, Robich MP, Lassaletta AD, Feng J, Laham RJ, Burgess T, Clements RT, Sellke FW. Resveratrol supplementation abrogates pro-arteriogenic effects of intramyocardial vascular endothelial growth factor in a hypercholesterolemic swine model of chronic ischemia. Surgery. 2011

102.  Pervaiz MH, Laham RJ. Distal anchoring technique: Yet another weapon for successful intervention. J Invasive Cardiol. 2011;23:295-296

103.  Levy MS, Laham RJ. Virtual histologic guidance of percutaneous peripheral atherectomy: The evolution of a new paradigm? J Invasive Cardiol. 2011;23:274-275

104.  Melman J, Levy MS, Laham RJ.  Intracardiac Echocardiography and fluoroscopy Guided Percutaneous Left Ventricular Pseudoaneurysm closure.  Catheter Cardiovasc Interv. 2011

BOOKS:

Angiogenesis and DMR, Edited by Roger Laham and Donald Baim.   Humana Press, 2005

Non-peer reviewed scientific or medical publications/materials in print or other media:

• Laham RJ, Josephson ME.  Silent Myocardial Ischemia: When is treatment required?  Journal of Critical Illness 1994;9(6):568-580.
• Caputo R, Laham RJ.  Acute heart failure in Intensive Care Medicine.  In Intensive Care Medicine.  Rippe JM, Irwin RS, Fink MP, Cerra FB (Eds).  Little, Brown Co., Third Edition, Boston.  1996:439-452.
• Laham RJ, Simons M.  Controversies in cardiopulmonary resuscitation.  In UpToDate, BDR, Inc.  1996;4(2).
• Laham RJ, Simons M.  Mechanical complications of acute myocardial infarction.  In UpToDate, BDR, Inc. 1996;4(2).
• Laham RJ, Simons M.  Role of revascularization in the management of unstable angina.  In UpToDate, BDR, Inc. 1996;4(2).
• Laham RJ, Post M, Simons M.  Basic mechanisms of restenosis.  UpToDate, BDR, Inc.  1997;5(1).
• Laham RJ.  Intraaortic Balloon Pump Counterpulsation.  UpToDate, BDR, Inc. 1997;5(1).
• Laham RJ, Baim DS. Primary Stenting in Acute Myocardial Infarction.  In UpToDate, BDR, Inc. 1997;5(1).
• Laham RJ, Simons M. Collaterals in Coronary Artery Disease.  UpToDate, BDR, Inc.  1997;5(1).
• Simons, M, Laham RJ. Therapeutic angiogenesis in myocardial ischemia. In: Simons and Ware, ed. Angiogenesis and Cardiovascular Disease: Oxford University press, 1999:289-320.
• Laham RJ, Simons M.  Growth Factor Therapy in Ischemic Heart Disease.  In Angiogenesis in Health and Disease.  Rubanyi G editor.  Marcel Dekker, Inc.  1999:451-475.
• Laham RJ, Simons M. Basic Fibroblast Growth Factor Protein for Coronary Artery Disease.  In: Handbook of myocardial Revascularization and Angiogenesis.  Martin Dunitz Ltd 1999; 175-187.
• Laham RJ, Josephson ME.  Silent Myocardial Ischemia.  Journal of Critical Illness 1999;14:334-41.
• Simons M, Laham RJ, Chronic Myocardial Ischemia: Contemporary Treatment Strategy.  Drugs of Today 1999;35:667-684.
• Laham RJ, Garcia L, Baim DS, Post M, Simons M. Therapeutic Angiogenesis Using Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Using Various Delivery Strategies. Current Interventional Cardiology Reports 1999;1:228-233.
• Garcia L, Baim DS, Post M, Simons M, Laham RJ. Therapeutic Angiogenesis Using Endocardial Approach to Administration: Techniques and Results. Current Interventional Cardiology Reports 1999;1:222-227.
• KumarA, Gamghir DS, Laham RJ.  Current Status of Therapeutic Angiogenesis.  Indian Heart Journal 2000;52:604-614.
• Simons M, Laham RJ, Post M, Sellke FW.  Angiogenic Growth Factor Trials for Patients with Advanced Coronary Disease.  Biodrugs 2000;14:13-20.
• Laham RJ.  Angiogenesis: Clinical Trials.  The Canadian Journal of Cardiology 2001;17:29-32A.
• Gibson CM, Carrozza JP, Laham RJ, Baim DS.  Clinical trials of primary percutaneous coronary intervention in acute myocardial infarction-I.  UpToDate, BDR, Inc. 2004.
• Gibson CM, Carrozza JP, Laham RJ, Baim DS.  Clinical trials of primary percutaneous coronary intervention in acute myocardial infarction-II.  UpToDate, BDR, Inc. 2004.
• Gibson CM, Carrozza JP, Laham RJ, Baim DS.  Clinical trials of primary percutaneous coronary intervention in acute myocardial infarction-III.  UpToDate, BDR, Inc. 2004.
• Laham RJ, Aroesty J.  Intraaortic balloon pump counterpulsation.  UpToDate, BDR, Inc. 2004.
• Laham RJ, Post M, Simons M.  Molecular biology of restenosis: Role of cytokines and vascular remodeling. UpToDate, BDR, Inc. 2004.
• Laham RJ, Simons M. Transmyocardial laser revascularization for management of refractory angina.  UpToDate, BDR, Inc. 2004.
• Laham RJ, Simons M.  New medical and invasive therapies for angina pectoris. UpToDate, BDR, Inc. 2004.
• Laham RJ, Simons M.  Mechanical complications of acute myocardial infarction. UpToDate, BDR, Inc. 2004.
• Laham RJ, Simons M.  Controversies in cardiopulmonary resuscitation.  UpToDate, BDR, Inc. 2004.
• Laham RJ, Simons M. Controversies in cardiopulmonary resuscitation.  UpToDate, BDR, Inc. 2004.
• Breall J, Laham RJ, Aroesty J, Simons M.  Coronary arteriography and revascularization for unstable angina or non-ST elevation (non-Q wave) acute myocardial infarction.  UpToDate, BDR, Inc. 2004.        

Abstracts not published in complete form  (not updated):

1.  Wood MJ, Cohen DJ, Laham RJ, Caputo RP, Carrozza JP, Lopez JJ, Baim DS.  Catheter based revascularization in patients with prior coronary bypass surgery-increasing prevalence and new device use in 1993 compared to 1988.  Circulation 1994;90:I-63.

2.  Laham RJ, Carrozza JP, Kuntz RE, Baim DS, Aroesty JM, Cohen DJ.  Intraaortic balloon pump counterpulsation in octogenarians: outcome and complications.  J Am Coll Cardiol 1995:48A.

3.  Laham RJ, Kuntz RE, Baim DS, Simons M.  Biological activity of human coronary atherectomy tissue.  Presented at the Greenfield Symposium, Duke University Medical Center, Durham, NC, June 16th 1995.

4.  Laham RJ, Kuntz RE, Baim DS, Ware JA, Slayter H, Schnitt SJ, Stillman IE, Simons M.  Smooth Muscle Cell Proliferation, Growth and Migration in Primary and Restenotic Human Atherosclerotic Tissue.  J Am Coll Cardiol 1996;27:254A.

5.  Laham RJ, Josephson ME.  A Prospective Evaluation of the Outpatient Initiation of Antiarrhythmic Therapy for Supraventricular Tachyarrhythmias.  J Am Coll Cardiol 1996;27:47A.

6.  Sibinga NE, Hsieh CM, Perella MA, Lee WS, Foster LC, Laham RJ, Sage EH, Lee ME, Haber E.  Collagen VIII in vascular remodeling.  Circulation 1996;94:I-350.

7.  Laham RJ, Tofukuji M, Sellke FW, Simons M.  Vascular Endothelial Growth Factor (VEGF) Affects Microvessels but not Epicardial Coronary Arteries and Veins.  Circulation 1997;96:I-551.

8.  Laham RJ, Rezaee M, Li J, Post M, Tofukuji M, Sellke FW, Simons M.  Adaptive Responses of Ischemic Microvessels: Increased Expression of Inducible Nitric Oxide Synthase (iNOS) but not Endothelial NOS (eNOS). Circulation 1997; 96:I-355.

9. Laham RJ, Sellke F, Pearlman J. Magnetic Resonance Blood-Arrival Maps Provides Acccurate Assessment of Myocardial Perfusion and Collaterization in Therapeutic Angiogenesis.  Circulation 1998;97:I-666.

10. Laham RJ, Li J, Sellke F. Myocardial Ischemia Induced Endothelium-Dependent Vasodilation Unrelated to Excess Nitric Oxide Generated by Increased Expression of Inducible Nitric Oxide Synthase. Circulation 1998;97:I-373.

11.  Laham RJ, Rezaee M, Garcia L, Post M, Sellke FW, Baim DS, Simons M.  Tissue and Myocardial Distribution of Intracoronary, Intravenous, Intrapericardial, and Intramyocardial 125I-Labeled Basic Fibroblast Growth Factor (bFGF) Favor Intramyocardial Delivery.  J Am Coll Cardiol; 1999;35:10A.  
12. Sato K, Post M, Johnson R, Pearlman JD, Laham RJ, Sellke FW. How To Evaluate The Effect Of Angiogenic Strategies On Regional Myocardial Blood Flow?  Circulation 1999;98.

13.  Pearlman JD, Wu Y, Simons M, Baim DS, Laham RJ.  Correspondence of BIOSENSE-Guided Endocardial Catheter Maps With MRI: Influence of Number of Locations Sampled.  Journal of the American College of Cardiology 2000:35:81A

14.  Leon MB, Baim DS, Moses JW, Laham RJ, Knopf W.  A Randomized Blinded Clinical Trial Comparing Percutaneous Laser Myocardial Revascularization (Using Biosense LV Mapping) vs Placebo in Patients with Refractory Coronary Ischemia. Circulation 2000

15.  Laham RJ, Sellke FW, Baim DS, Simons M.  Outcome Measures in Angiogenesis and Laser Trials: Natural history of No-option Patients with Ischemic Heart Disease Who Are Not Candidates for PTCA or CABG and Who Remain Symptomatic on Medical Therapy.  Journal of the American College of Cardiology 2001:37:648A

16.  Laham RJ, Post M, Sellke FW, Simons M.  Tissue and Myocardial Distribution of Endocardial vs Epicardial Intramyocardial Delivery of 125-I-Labeled Basic Fibroblast Growth Factor.  Journal of the American College of Cardiology 2001:37:648A

17.  Beran GP, Post M, Simons M, Glogar D, Laham RJ.  Biosense NOGA Mapping for Detection of Myocardial Ischemia: Comprehensive Assessment in 74 Pigs.  Journal of the American College of Cardiology 2001:37:648A

18.  Laham RJ,  Simons M, Sellke FW, Mannam A, Cohen DJ.  "Physiological" Placebo in clinical angiogenesis and laser myocardial revascularization studies underscores the importance of blinding.  Circulation 2001

19.  Laham RJ, Mannam A, Cohen DJ, Neimann D, Rooney P, Sellke FW.  Clinical Angiogenesis and laser myocardial revascularization studies: the need for better outcome measures.  Circulation 2001

20.  Ruel M, Laham RJ, Niemann D, Sellke FW, Parker JA.  Late Nuclear Perfusion Imaging Follow-up after Perivascular Implantation of FGF-2.  Circulation 2001

21.  Laham RJ, Cohen DJ, Carrozza JP, Ho KKL, Mannam A, Sellke FW.  Longevity of the Placebo Effect in Patients Enrolled in Angiogenesis and Laser Myocardial Revascularization Trials.  Journal of the American College of Cardiology 2002

22.  Gao L, Laham R, Post M, Simons M, Pearlman J, Parker A.  A Rest Bolus-Transit MRI Examination with Space-Time Maps Showing Delayed Equitime Is Comparable to Stress TC-99m-Sestamibi for Identifying Myocardium at Risk. Circulation 2002

23,  Ruel M, Khan T, Laham R, Sellke FW.  Inhibited Angiogenic Response to Surgical FGF-2 Protein Therapy in a Swine Model of Endothelial Dysfunction.  Circulation 2002

24.  Voisine P, Ruel M, Bianchi C, Khan TA,  Xu S, Feng J, Laham RJ, Sellke FW. Hypercholesterolemia-Induced Resistance to Exogenous FGF-2 Effects on Endothelial Function in a Swine Model of Chronic Myocardial Ischemia. Can J Cardiol 2003; 19 Suppl. A:158A.

25.  Voisine P, Yadlapalli N, Khan TA, Laham RJ, Roy-Chaudhury P, Burnett SK, Bianchi C, Sellke FW, Sukhatme VP. Expression of a Platelet-Derived Growth Factor (PDGF)-Signaling Pathway in a Porcine Model of Arterio-Venous (AV) Graft Stenosis. Can J Cardiol 2003; 19 Suppl. A:183A.

26.  Voisine P, Ruel M, Bianchi C, Khan T, Xu Shu, Feng J, Li J, Laham RJ, Sellke FW. Chronic Hypercholesterolemia Induces Resistance to the Exogenous Effects of FGF-2 on Endothelial Function in a Swine Model of Chronic Myocardial Ischemia. Circulation 2003  

27.  Wu G, Rana J, Rosinberg A, Li J, Selke F, Laham RJ.  SDF-1α Upregulates COX-2 Gene Expression via p38 MAPK in Vascular Endothelial Cells and Mouse Model of Myocardial Infarction.  Circulation 2004.

28.  Wu G, Rana J, Laham RJ, Sellke FW, Li J.  Involvement of COX-2 in VEGF-induced Angiogenesis via P38 and JNK Pathway in Endothelial Cells.  Circulation 2004

29.  Voisine P, Rosinberg A, Shamis Y, Wu G, Yeon S, Applebaum E, Mitrani E, Donnel-Fink L, Sellke FW, Laham RJ.  Skin-Derived Micro-Tissue Autotransplantation as a Novel Approach for Therapeutic Angiogenesis.  Circulation 2004 (AHA 2004)

30.  Bridges J, Pinto D, Pickett C, Ho K, Cutlip D, Laham RJ, Cohen DJ, Carrozza JP.  Pattern of Brachytherapy Failure in Unselected Patients Treated With Gamma and Beta Radiation for Saphenous Vein Graft In-Stent Restenosis.  Journal of the American College of Cardiology 2004

31.  Rosinberg A, Voisine P, Wu G, Applebaum G, Yeon S, Lee Seung, Carrozza JP, Sellke FW, Laham RJ.  Autologous Myotissue Transplantation in a Porcine Myocardial Infarction Model Results in Improved Function and Decreased Infarct Size.  Journal of the American College of Cardiology 2005

32.  Shie JL, Luo J, Laham RJ, Sellke F, Li J.  RTEF-1, A Novel Transcriptional Stimulator, Regulates FGF Receptor 1 Expression in Hypoxic Endothelial Cells.  Circulation 2005

33.  Wykrzykowska J, Lee S, Mieno S, Appelbaum E, Donnell-Fink L, Boodhwani M, Li J, Sellke F, Gibson CM, Carrozza JP, Laham RJ.  Myotissue Implants Into Myocardial Infarct Zone Decreases Infarct Size and Improves Left Ventricular Function in Infarct Scar with Increased Cardiac Stem Cells.  Circulation 2005, AHA abstract

34.  Boodhwani M, Voisine P, Feng J, Xu S, Li J, Mieno S, Ramlawi B, Bianchi C, Laham RJ, Sellke F.  Atorvastatin Impairs Myocardial Angiogenic Response to Chronic Ischemia in Normocholesterolemic Swine.  Circulation 2005

35.  Wu G, Rana J, Wykrzykowska J, Kang P, Li J, Gibson CM, Sellke FW, Laham RJ. Exercise-Induced Expression of Angiogenic Cytokines in Normal and Infarcted Hearts.  Circulation 2005